高级搜索
肺癌脑转移患者化疗配合放疗的临床研究[J]. 肿瘤防治研究, 2003, 30(03): 225-227. DOI: 10.3971/j.issn.1000-8578.2717
引用本文: 肺癌脑转移患者化疗配合放疗的临床研究[J]. 肿瘤防治研究, 2003, 30(03): 225-227. DOI: 10.3971/j.issn.1000-8578.2717
The clinical research of the radiotherapy and chemotherapy for patients of brain metastases from lung cancer[J]. Cancer Research on Prevention and Treatment, 2003, 30(03): 225-227. DOI: 10.3971/j.issn.1000-8578.2717
Citation: The clinical research of the radiotherapy and chemotherapy for patients of brain metastases from lung cancer[J]. Cancer Research on Prevention and Treatment, 2003, 30(03): 225-227. DOI: 10.3971/j.issn.1000-8578.2717

肺癌脑转移患者化疗配合放疗的临床研究

The clinical research of the radiotherapy and chemotherapy for patients of brain metastases from lung cancer

  • 摘要: 目的 比较化疗配合放疗与单纯放疗治疗肺癌脑转移的疗效、生存时间及不良反应。方法 将1 999年 8月~ 2 0 0 2年 2月间所治疗的 82例多发性脑转移患者随机分为单纯放疗组 (放疗组 4 4例 )和放化疗综合组 (综合组 38例 )进行治疗。放疗组 :全脑常规放疗 (30~ 4 0 )Gy/ (3~4 .5 )周。综合组 :放疗方法与单纯放疗组相同, 在放疗前后或放疗同时进行 3~ 4周期化疗。化疗则采用EP方案或MVP方案, 均 2 1天至 2 8天重复。结果 完成治疗且可评估共有 78例 (放疗组 4 3例, 综合组 35例 )。放疗组和综合治疗组总有效率分别为 83.5 % (37/ 4 3例 )和 85 .7% (30 / 35例 ), P >0 .0 5。治疗后中位生存时间 :放疗组为 5 .1月, 综合组为 7.3月 ;一年生存率 :放疗组 9.3% (4 / 4 3), 综合组 2 5 .7% (9/ 35 )。两组中位生存期及一年生存率均有显著差异性 (P <0 .0 5 )。综合组的胃肠道反应及骨髓抑制高于放疗组, 但大多数患者均能耐受。结论 肺癌脑转移患者放化综合治疗可以延长生存时间

     

    Abstract: Objective To compare the therapeutic effects of brain metastases from lung cancer between radiotherapy combined with chemotherapy and radiotherapy alone. Methods 82 cases with brain metastases from lung cancer were treated from August 1999 to February 2002. Patients were randomly divided into 2 groups, including simple irradiation group and combined group. 44 cases in simple irradiation group received whole brain irradiation to a total dose of 30~40Gy; while in combined group there were 38 cases receive

     

/

返回文章
返回